Zura Bio Ltd (ZURA)
Zura Bio Ltd (ZURA)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -24,223 | -17,175 | -18,040 | -33,435 |
| Share-based compensation expense | 5,008 | 2,577 | 2,379 | 7,376 |
| Depreciation and amortization | 16 | 15 | 14 | 20 |
| Foreign exchange transaction loss | -2 | -11 | -6 | -67 |
| Gain on extinguishment of baffx17 liability | NaN | 5,000 | NaN | NaN |
| Other non-cash items, net | NaN | -4 | NaN | NaN |
| Loss on disposal of property and equipment | -3 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | -1,493 | -372 | 780 | 249 |
| Other assets | NaN | 0 | 814 | NaN |
| Accounts payable and accrued expenses | -1,222 | -3,082 | 1,791 | -872 |
| Net cash used in operating activities | -18,923 | -22,278 | -15,444 | -27,093 |
| Purchase of property and equipment | 13 | 17 | 32 | 64 |
| Net cash used in investing activities | -13 | -17 | -32 | -64 |
| Proceeds from issuance of class a ordinary shares in connection with february 2026 equity offering, net of 8.0 million of underwriters fees and discounts | 123,875 | NaN | NaN | NaN |
| Proceeds from issuance of pre-funded warrants in connection with february 2026 equity offering, net of 0.7 million of underwriters fees and discounts | 11,248 | NaN | NaN | NaN |
| Proceeds from issuance of class a ordinary shares in connection with a sale under the atm, net of 0.2 million of commissions | 0 | 0 | 0 | 5,093 |
| Issuance of class a ordinary shares upon exercise of pre-funded warrants | NaN | 3 | NaN | NaN |
| Proceeds from exercise of stock options | 0 | 17 | 0 | 90 |
| Proceeds from exercise of pre-funded warrants | NaN | NaN | 3 | NaN |
| Restricted stock units withheld to pay employee withholding taxes | NaN | 7 | 0 | 34 |
| Consideration paid for athanor agreement | NaN | 7,325 | NaN | NaN |
| Net cash provided by financing activities | 135,123 | -7,315 | 3 | 5,149 |
| Net increase (decrease) in cash and cash equivalents | 116,187 | -29,610 | -15,473 | -22,008 |
| Cash and cash equivalents, beginning of period | 109,407 | 176,498 | 176,498 | NaN |
| Cash and cash equivalents, ending of period | 225,594 | -29,610 | 139,017 | NaN |